-

Meridian Bioscience Announces Health Canada License for Alethia® CMV Assay

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its Alethia® CMV assay. The addition of CMV expands Meridian's existing Alethia menu, which includes C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian's molecular diagnostic offerings in the Canadian market.

The Alethia platform delivers accurate molecular results in less than an hour to support evidence-based clinical decisions. With a small footprint and simple workflow, Alethia helps labs run efficiently while delivering reliable molecular results. The platform uses LAMP technology (loop-mediated isothermal amplification) for a cost-effective molecular solution.

With the Alethia CMV assay, Meridian delivers highly sensitive molecular detection with rapid turnaround time. Nearly 1 in 4 women carry cytomegalovirus (CMV), the most common congenital infection transmitted from mother to baby during pregnancy.1,2 Every year 1 in 200 babies are born with congenital CMV, and yet, the majority of pregnant women have never heard of it.3 Alethia CMV enables early detection of congenital CMV, which is vital in guiding appropriate clinical care for newborns. Congenital CMV testing empowers physicians and families with a full understanding of their newborn’s health prior to leaving the hospital.

“We are excited about the expanded menu offering of CMV on our Alethia platform in Canada. This allows Meridian to provide an important diagnostic solution for customers in the Canadian market. By utilizing saliva as the sample type, the assay delivers an easy-to-collect specimen for congenital CMV testing,” said Michelle Bosch, Vice President of Global Marketing. “The Alethia CMV assay provides clinicians with a valuable tool to aid in the diagnosis of congenital CMV.”

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian’s website address is www.meridianbioscience.com.

1.

Silasi M, Cardenas I, Racicot K, Kwon J-Y, Aldo P, Mor G. VIRAL INFECTIONS DURING PREGNANCY. American Journal Of Reproductive Immunology (New York, NY : 1989). 2015;73(3):199-213. doi:10.1111/aji.12355. 2. Marchofdimes.org. (2018).

2.

Cytomegalovirus and pregnancy. [online] Available at: https://www.marchofdimes.org/find-support/topics/planning-baby/cytomegalovirus-and-pregnancy.

3.

Congenital CMV Facts. Centers for Disease Control and Prevention. https://www.cdc.gov/cytomegalovirus/congenital-infection/index.html.

 

Contacts

Michelle Bosch, Vice President, Global Commercial Marketing and Business Management, DIAGNOSTICS
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com or michelle.bosch@meridianbioscience.com

Meridian Bioscience, Inc.


Release Versions

Contacts

Michelle Bosch, Vice President, Global Commercial Marketing and Business Management, DIAGNOSTICS
Meridian Bioscience, Inc.
Phone: 513.271.3700
Email: mbi@meridianbioscience.com or michelle.bosch@meridianbioscience.com

More News From Meridian Bioscience, Inc.

Meridian Bioscience and 4bases Announce Collaboration to Enable Rapid, Globally Scalable Next-Generation Sequencing Workflows

CINCINNATI--(BUSINESS WIRE)--The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced a collaboration with 4bases SA to support the global deployment of KaryoSolver, a next-generation cytogenetics assay, through advanced assay stabilization. KaryoSolver represents a significant step forward in cytogenetics. Traditional workflows rely on multiple complementary tests, often taking days to deli...

Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced that a broad portfolio of its Alethia molecular assays has successfully achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746. The certification, issued by GMED (Notified Body 0459), confirms that the following Alethia assays and associated external controls are compliant with IVDR requirements and...

Meridian Life Science Expands Ambient-Stable NGS Portfolio with the Launch of a Lyophilized Enzymatic DNA Fragmentation Kit

CINCINNATI--(BUSINESS WIRE)--The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of its Lyophilized NGS Enzymatic DNA Fragmentation Kit. The kit is designed for ambient-temperature (15-25⁰C) shipping and storage, eliminating the need for cold-chain requirements and helping laboratories simplify their NGS sample preparation workflows. The launch of this new kit extends Meridia...
Back to Newsroom